Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.32 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3059616 | 1.00 | SLC1A3 (0.52) | SLC1A3SLC1A2SLC1A1TP53SLC7A5 | |
| SCHEMBL26138067 | 0.84 | SLC1A3 (0.58) | SLC1A3SLC1A2SLC1A1TP53SLC7A5 | |
| SCHEMBL9858433 | 0.77 | SLC1A3 (0.60) | SLC1A3SLC1A2SLC1A1TP53SLC7A5 | |
| SCHEMBL10353879 | 0.74 | — | — | |
| SCHEMBL6870066 | 0.74 | SLC1A3 (0.62) | SLC1A3SLC1A2SLC1A1TP53SLC7A5 | |
| SCHEMBL2717757 | 0.74 | SLC1A3 (0.62) | SLC1A3SLC1A2SLC1A1TP53SLC7A5 | |
| SCHEMBL9213452 | 0.72 | SLC1A3 (0.60) | SLC1A3SLC1A2SLC1A1TP53SLC7A5 | |
| SCHEMBL9675609 | 0.71 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1TP53SLC7A5 | |
| SCHEMBL9676557 | 0.71 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1TP53SLC7A5 | |
| SCHEMBL9675622 | 0.71 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1TP53SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | SLC1A3 1658/4885SLC1A2 1937/4885SLC1A1 1616/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | SLC1A3 1658/4885SLC1A2 1937/4885SLC1A1 1616/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | SLC1A3 1658/4885SLC1A2 1937/4885SLC1A1 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.